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Abstract 
Plasminogen activation is regulated by the interaction between urokinase-type plasminogen activator (UPA) and its specific glycolipid-anchored 
cell surface receptor (uPAR). uPAR is composed of three homologous domains and is the only multi-domain member of the Ly-6 family of 
glycolipid-anchored membrane proteins. Recent evidence has highlighted similarities between the individual domains of uPAR and the large family 
of secreted, single domain snake venom a-neurotoxins, suggesting that uPAR may adopt the same gross folding pattern as these structurally well 
characterized proteins. Structural aspects of the binding between ol-neurotoxins and the acetylcholine receptor may have a major influence on future 
studies of the interaction between uPA and uPAR. 
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1. Introduction 
Specific binding sites for urokinase-type plasminogen 
activator (UPA) are present on many cells, including neu- 
trophils, monocytes, migrating keratinocytes and certain 
cancer cells [14]. The cellular binding is of high affinity 
(Z&=0.1-lnM), and involves the interaction between a 
single, specific membrane protein (uPAR) and the NH,- 
terminal growth factor-like module of UPA [5,6]. uPAR 
can bind both active two-chain UPA and its single-chain 
proenzyme (pro-uPA) [7], and receptor-bound UPA can 
be inactivated by its specific inhibitors, the serpins PAI- 
and PAI- [8,9]. 
The primary function of uPAR is to strictly confine 
uPA-catalyzed plasminogen activation to the cell sur- 
face. This is acheived not only by the high-affinity bind- 
ing but also by the favourable kinetics of the individual 
reactions in this reciprocal zymogen activation system 
which lead to a greatly enhanced generation of cell-asso- 
ciated plasmin [ 10,111. These mechanisms are considered 
to play a major role in mediating the controlled break- 
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down of extracellular matrix during cell migration and 
invasion in many conditions, including cancer invasion 
and metastasis (as reviewed in [12]). 
The purpose of this minireview is to summarize recent 
structural data concerning the multi-domain organisa- 
tion of uPAR and to relate these to the high-affinity 
interaction between UPA and uPAR. 
2. Primary structure and membrane attachment of uPAR 
The specific binding of UPA to cells was first observed 
with human monocytes and the monocyte-like cell line 
U937 [l]. The membrane protein responsible for this 
binding was later purified and characterized from phor- 
bol ester stimulated U937 cells [13,14] and was desig- 
nated as the UPA receptor (uPAR) [15]. It is a hetero- 
genously glycosylated, single-chain polypeptide of 
M,=50-60,000 which decreases to 35,000 upon degly- 
cosylation. Sequencing of human uPAR cDNA revealed 
that the protein is encoded as a 335 residue polypeptide 
of which the first 22 amino acids constitute the signal 
peptide [16]. The nascent uPAR contains five potential 
glycosylation sites for N-linked carbohydrate (Asn-Xaa- 
Thr/Ser). Murine, bovine and rat uPAR cDNAs with 
similar characteristics have also been sequenced [ 17-191. 
Despite being an integral membrane protein there is 
no obvious transmembrane segment in the cDNA 
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derived sequence of uPAR. The reason for this apparent 
discrepancy is that uPAR is anchored to the plasma 
membrane by a glycolipid (glycosyl-phosphatidylinosi- 
tol) moiety which is added concurrently to the posttrans- 
lational removal of a COOH-terminal signal sequence 
[20]. Amino acid composition [20] and mutational [21] 
analyses indicate that this processing is most likely to 
occur at Gly2*’ of human uPAR, generating a mature 
protein composed of residues l-283. As a direct conse- 
quence of its glycolipid anchorage uPAR is absent from 
the cell surface of peripheral blood leukocytes affected 
by the haemapoietic stem cell disorder paroxysmal noc- 
turnal haemoglobinuria [2], the protein being secreted 
from these cells in a truncated form [22]. The possible 
biological significance of the glycolipid-anchorage of 
uPAR has been reviewed elsewhere [23]. 
3. Internal sequence homologies in uPAR 
The entire sequence of mature uPAR is composed of 
three repeats of approximately 90 residues. The consen- 
sus sequence derived from these repeats is primarily de- 
fined by a conserved pattern of cysteine residues, which 
constitute 10% of the protein, but also includes specified 
gap regions [24]. These repeats appear to be rather dis- 
tantly related as their sequence identity is less than 20% 
within human, murine or bovine uPAR, whereas the 
interspecies conservation of the individual repeats is 
greater than 60% [I 81. This primary sequence data led to 
the assumption that these repeats are autonomous struc- 
tural entities and a three domain model for uPAR was 
proposed [23,24]. The validity of this model has been 
supported by several independent observations. Firstly, 
limited proteolysis of uPAR preferentially leads to cleav- 
age of the polypeptide connecting the first and second 
repeats (Fig. l), a property typical of an interdomain 
linker region. Secondly, studies on the gene structure 
show that the protein repeats of uPAR are encoded by 
symmetrical exon sets flanked by intron/exon boundaries 
of the same phase i.e. type-l [25]. Thirdly, as discussed 
in detail below, single domain proteins homologous to 
the individual repeats of uPAR, i.e. conforming to the 
consensus sequence that defines them, have been identi- 
fied. 
4. Relationship between uPAR and the Ly-6 gene family 
Protein database searching using the consensus 
sequence of the putative domains of uPAR revealed 
homology to a diverse group of single domain glycopro- 
teins [24]; see Fig. 2, upper panel. This group includes a 
gene family of murine leukocyte antigens collectively 
Fig. 1. Primary structure of uPAR. The primary sequence of human uPAR is shown as encircled amino acids in the single letter code. Circles joined 
by a black bar represent disulphide bonded cysteine residues (note that only the disulphide bonds of the NH,-terminal domain have been determined 
experimentally [30]; the remaining disulphide bonds have been located according to the consensus shown in Fig. 2). Diamonds represent potential 
attachment sites for N-linked carbohydrate. The large arrows indicate positions corresponding to the presence of introns in the “PAR gene [2.5]. The 
smaller arrows identify peptide bonds that are extremely susceptible to proteolysis in the native non-denatured protein;- Chym., chymotrypsin [24]; 
Hnel., human neutrophil elastase; and Trap., trypsin (cleavage sites were identified by laser desorption mass spectrometry; Rahbek-Nielsen and Ploug, 
unpublished data). 
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Fig. 2. Sequence alignment of the uPAR/Ly-6 family and the snake venom neurotoxins. The upper panel shows an alignment of the individual domains 
from the uPAR/Ly-6 family of glycolipid-anchored membrane proteins. The lower panel shows an equivalent alignment for the secreted single domain 
proteins belonging to the various subgroups and homologs of the snake neurotoxin family. Distances between the conserved cysteines are shown, 
highlightning that the variability both between and within the individual groups is essentially confined to the loop regions (covered by the shaded 
boxes). The number of sequences defining each group is shown in brackets (the uPAR domains are from four different species). Additional, 
non-conserved cysteine pairs found in all members of the uPAR/Ly-6 family, two 'weak' neurotoxins and the long neurotoxins are situated outside 
of the globular core, within the long loops in the snake neurotoxin model. It should be noted that the NH2-terminal domain of uPAR is uniquely 
lacking a cysteine pair conserved in all other proteins represented in this alignment (shown as a dashed line). The arrowheads denote the positions 
of the single intradomain i tron dividing the exons encoding the consensus sequence where known. 
known as Ly-6 and the regulatory complement compo- 
nent CD59 (MIRL, membrane inhibitor of reactive 
lysis). Like uPAR these are all glycolipid-anchored mem- 
brane proteins and have gene organizations comparable 
to those segments of the uPAR gene encoding the indi- 
vidual domains [26,27]. Of these proteins only CD59 has 
been studied at the structural level, an incomplete dis- 
ulphide structure consistent with that of the NH2-termi- 
nal domain of uPAR [28] and partial IH-NMR assign- 
ments [29] having recently been reported. 
5. Similarity to snake venom ~-neurotoxins - a possible 
template for the gross folding of uPAR 
Knowledge of the disulphide structure of the NH2- 
terminal domain of uPAR [30] prompted us to re-search 
the protein data base for homologies using a shorter 
consensus sequence or motif. The sequence C C X X X 
X C N was chosen as (a) the asparagine is the only 
invariant non-cysteine r sidue in the uPAR/Ly-6 consen- 
sus, and (b) the motif forms a short loop structure as its 
second and third cysteines are disulphide bonded. The 
search identified the large family of snake venom 
~-neurotoxins, exemplified by the acetylcholine r ceptor 
antagonist c~-bungarotoxin [31-33]. These secreted pro- 
teins are of similar size to the uPAR/Ly-6 domains, and 
most importantly have eight cysteine residues that are 
comparably spaced and identically paired to those of 
uPAR (Fig. 2). A similar relationship between Ly-6 and 
the snake neurotoxins has been independently proposed 
by others based on linear alignment of sequences [34]. It 
should be pointed out that this relationship was not iden- 
tified in the searches which originally revealed the uPAR/ 
Ly-6 relationship as the neurotoxins lack a specific dis- 
ulphide pairing which is conserved in all members of the 
Ly-6 family (Fig. 2). Further support for a relationship 
between these two groups of proteins again comes from 
the similarity in the structure of the uPAR, Ly-6 and 
CD59 genes, and that of the only snake toxin analyzed 
at this level, erabutoxin-c [35]. These similarities may be 
taken to suggest that these proteins hare a similar three- 
dimensional folding motif. 
Fortuitously the snake neurotoxin family has been ex- 
tremely well studied at the structural level, with over 15 
known X-ray and NMR structures. Their overall folding 
consists of three adjacent loops participating in a fiat 
triple-stranded antiparallel r-sheet, emerging from a 
small globular core stabilized by the four conserved is- 
ulphide bonds. Consistent with this folding the CD spec- 
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trum of recombinantly expressed uPAR (Casas-Finet 
and Ploug, unpublished data) is comparable to those of 
the a-neurotoxins which show essentially only &struc- 
ture [32,33]. Recently a gross folding toplogy of the Ly-6 
family member CD59 has been proposed based on al- 
most complete ‘H-NMR assignments. This was found to 
be compatible with an a-neurotoxin-like structure, par- 
ticularly in terms of P-sheet formation [29]**. 
Fig. 3 shows the primary sequence of the NH,-termi- 
nal domain of uPAR superimposed onto an a-neuro- 
toxin model structure which has been achieved with only 
minor modifications. It is apparent from the linear align- 
ment in Fig. 2 and the model in Fig. 3 that the modifica- 
tions that are necessary occur outside of the cysteine-rich 
globular core. The distal parts of each of the three major 
loops coincide with gap regions originally defined in the 
uPAR consensus equence and in general such gap re- 
gions are predicted to occur in exposed surface loops 
[36]. The additional non-conserved pair of cysteines pres- 
ent in all uPAR domains and the Ly-6 family fall within 
loop 1 of the model. A comparable non-conserved cyste- 
ine pair also occurs in loop 2 of the long neurotoxins as 
well as in loop 1 of two ‘weak’ neurotoxins (Fig. 2). 
This model, whilst providing compelling evidence for 
a structural relationship between these proteins, reveals 
some striking differences between uPAR and all of the 
other proteins, which may be related to the unique multi- 
domain structure of uPAR. The model shows that the 
consensus motif used to detect he homology to the snake 
neurotoxins forms a short loop within the globular core 
of the protein. In the neurotoxins residues within this 
loop are involved in interactions considered important 
for the structural maintenance of the protein, the side 
chain of the invariant asparagine being engaged in sev- 
eral hydrogen bonds that anchor the loop to the globular 
core [37,38] and the highly conserved third position of 
the loop motif C C X X X X C N (X being either Asp 
(85%) or Asn/Glu (15%)) being able to form a salt-bridge 
(or hydrogen bond) to the terminal a-amino group 
[3 1,321. This position is also conserved in the NH,-termi- 
nal domain of uPAR and all the single domain Ly-6 
family proteins. However due to its multi-domain struc- 
ture the potential formation of a similar salt-bridge is 
precluded in the second and third domains of uPAR. It 
is therefore perhaps not surprising, in light of the pro- 
posed model structure, that the ‘carboxyl terminal’ se- 
quences of these two domains of uPAR do not conform 
to the archetypal C C X X D X CN consensus motif, but 
have the aspartic acid replaced by the non-conservative 
substitutions. threonine and serine. 
**Subsequent to submission of this review two almost identical solution 
structures of CD59 determined by NMR have been independently re- 
ported [49,SO]. Both structures conform well to those ofthe a-neurotox- 
ins, the major difference being the presence of a short helical element 
in the outer part of loop 3 in CD59. 
n 
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Fig. 3. The NH,-terminal sequence of uPAR superimposed onto a 
simplified folding model of the snake neurotoxins. The amino acid 
sequence of the NH,-terminal domain of uPAR (as encoded by the first 
exon-set in the gene) is ‘threaded’ onto a representative a-neurotoxin 
backbone [31]. Cysteine residues are highlighted, as are Th?’ and Val”’ 
the predicted positions of the cysteine pairing uniquely lacking in this 
domain of uPAR. The arrow denotes the position of the single intrado- 
main intron. The inset shows the majorp-sheet structure in a simplified 
snake neurotoxin model. 
Another major, and more surprising, difference be- 
tween uPAR and the other single domain proteins is that 
the NH,-terminal domain of uPAR lacks one of the cys- 
teine pairs that is strictly conserved in all of the Ly-6 
family, the snake neurotoxins and the second and third 
domains of uPAR. The significance of this is unclear but 
it may be related to the unique multi-domain structure 
of uPAR which, as discussed in the following section, 
may be of critical importance for its function. 
6. Structural aspects of the uPA/uPAR interaction 
The uPAR binding-site of UPA has been localized to 
the growth factor-like module of this mosaic protein [6] 
which also contains a kringle module and a serine pro- 
tease domain. The growth factor-like module of UPA 
(residues 4-43) retains the high affinity binding to uPAR 
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when isolated from the rest of the molecule [39]. The 
recently solved solution structure of the entire NH,-ter- 
minal fragment of uPA (i.e. the growth factor-like mod- 
ule and the kringle module) provides an explanation for 
this as these two domains were shown to be structurally 
independent with no interdomain interactions 1401. In 
contrast to this the multi-domain structure of uPAR ap- 
pears to be essential for its high-affinity interaction with 
uPA. Ligand binding involves the NH,-terminal domain 
of uPAR [24], but proteolytic liberation of this domain 
has recently been shown to cause a dramatic decrease in 
its binding affinity both for uPA and the low molecular 
weight fluorophore 8-anilino- 1 -naphthalene sulphonate 
(ANS) 1411. This has been interpreted to suggest that 
interdomain interactions within uPAR play a crucial role 
in ligand binding, either by stabilizing a discrete confor- 
mation of the NH,-terminal domain or being directly 
involved in the ligand binding interaction. Two interest- 
ing observations appertain to this. Firstly, intermolecu- 
lar domain associations have been found in the crystal 
structures of ol-cobratoxin [37] and cardiotoxin Vy [38], 
and also in the solution structure of K-bungarotoxin [42]. 
These toxins dimerize by intermolecular hydrogen bond- 
ing of the B-strand in the loop 3 regions, generating 
6-stranded antiparallel p-sheets. In Ic-bungarotoxin this 
dimerization is thought to generate the physiologically 
active species of the toxin [43]. Secondly, as emphasized 
previously, the NH,-terminal domain of uPAR uniquely 
lacks one of the cysteine pairs that is strictly conserved 
in the other proteins. This pair of cysteines are situated 
within the globular core at a position corresponding to 
the end of the B-strand in loop 3 in the neurotoxin struc- 
ture, where they may be expected to be intimately in- 
volved in the maintenance of this structure. The lack of 
these cysteines may be expected to lead to a conforma- 
tional instability in the isolated NH,-terminal domain of 
uPAR, which may be restricted by interdomain interac- 
tions in the intact protein. 
7. Perspectives 
The structural similarity between uPAR and the snake 
venom a-neurotoxins adressed in this review may prove 
to be useful not only in elucidating the structure of intact 
three domain uPAR, but may also give important leads 
as to structural aspects of the interaction between uPA 
and uPAR. Detailed structure-function analyses of 
a-neurotoxins by chemical modification, site-directed 
mutagenesis, X-ray crystallography and NMR [4447] 
suggest amultipoint interaction between these toxins and 
the acetylcholine receptor, involving several ocally sepa- 
rated structural elements within the neurotoxin. This has 
been verified by a recent solution structure solved for a 
complex of a-bungarotoxin and a synthetic peptide de- 
rived from the acetylcholine receptor [48]. A similar mul- 
167 
tipoint attachment is likely to occur between the growth 
factor-like module of uPA and the NH,-terminal domain 
of uPAR. 
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